BridgeMD
Compares treatment options for Reccurent/Metastatic Solid Tumor Disease
Official title Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
ClinicalTrials.gov ID: NCT07483658
What this study is testing
What is Androgen Deprivation Therapy (ADT)?
Androgen Deprivation Therapy (ADT) is an investigational medicine, being studied as a potential treatment for reccurent/metastatic solid tumor disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Histologically confirmed prostate adenocarcinoma.
- Prior radical prostatectomy with detectable PSA (≥0.2 ng/mL).
- No evidence of distant metastasis (confirmed via bone scan and CT/MRI or TEP-PSMA if PSA is above 0.5 ng /ml).
- Patient with Nodal recurrence within the pelvis are eligible
- ECOG performance status 0-2.
You likely can't join if
- Prior pelvic radiotherapy.
- Macroscopic local relapse on imaging
- Presence of metastatic disease.
- Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity.
- Uncontrolled comorbidities affecting study participation.
- Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).
See the full eligibility criteria
- Histologically confirmed prostate adenocarcinoma.
- Prior radical prostatectomy with detectable PSA (≥0.2 ng/mL).
- No evidence of distant metastasis (confirmed via bone scan and CT/MRI or TEP-PSMA if PSA is above 0.5 ng /ml).
- Patient with Nodal recurrence within the pelvis are eligible
- ECOG performance status 0-2.
- Age ≥ 18 years.
- Adequate baseline renal, hepatic, and hematologic function.
- Prior pelvic radiotherapy.
- Macroscopic local relapse on imaging
- Presence of metastatic disease.
- Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity.
- Uncontrolled comorbidities affecting study participation.
- Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).
The study team makes the final eligibility decision.
Where it's taking place
- Gatineau, Quebec, Canada
- Montreal, Quebec, Canada
- Québec, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gatineau, Quebec, Canada; Montreal, Quebec, Canada; Québec, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.